TRAIL promotes a pro-survival signal in erythropoietin-deprived human erythroblasts through the activation of an NF-kB/IkBalpha pathway. J Biol Regul Homeost Agents 2011;25(3):375-86.
. State of the art of the therapeutic perspective of sorafenib against hematological malignancies. Curr Med Chem 2012;19(28):4875-84.
. Fine tuning of protein kinase C (PKC) isoforms in cancer: shortening the distance from the laboratory to the bedside. Mini Rev Med Chem 2011;11(3):185-99.
. . .